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The efficacy of the combination of pyrimethamine and sulfadiazine for the treatment of congenital Toxo­
plasma gondii infection in rhesus monkeys was studied. The dosage regimen for pyrimethamine and sulfadi­
azine was established by pharmacokinetic studies in two monkeys. Those studies showed that the distributions 
of both drugs followed a one-compartment model. The serum elimination half-lives were found to be 5.2 h for 
sulfadiazine and 44.4 h for pyrimethamine. Sulfadiazine reached a maximum concentration in serum of 58.7 
|xg/ml, whereas a maximum concentration in serum of 0.22 fxg/ml was found for pyrimethamine. Ten monkeys 
were infected intravenously with T. gondii at day 90 of pregnancy, which is comparable to the second trimester 
of organogenetic development in humans. Treatment was administered to six monkeys, in whose fetuses 
infection was diagnosed antenatally. From the moment that fetal infection was proven, the monkeys were 
treated throughout pregnancy with 1 mg of pyrimethamine per kg of body weight per day and 50 mg of 
sulfadiazine per kg of body weight per day orally, The therapy was supplemented with 3.5 mg of folinic acid 
once a week. No toxic side effects were found with this drug regimen. The parasite was no longer detectable in 
the next consecutive amniotic fluid sample, taken 10 to 13 days after treatment was started. Furthermore, T. 
gondii was also not found in the neonate at birth. The parasite was still present at birth in three of four 
untreated fetuses that served as controls. Both drugs crossed the placenta very well. Concentrations in fetal 
serum varied from 0.05 to 0.14 |xg/ml for pyrimethamine and from 1.0 to 5.4 |xg/ml for sulfadiazine. In addition, 
pyrimethamine was found to accumulate in the brain tissue, with concentrations being three to four times 
higher than the corresponding concentrations in serum. Thirty percent of the sulfadiazine was found to reach 
the brain tissue when compared with the corresponding serum drug concentration. When administered early 
after the onset of infection, the combination of pyrimethamine and sulfadiazine was clearly etfective in reducing 
the number of parasites in the fetus to undetectable levels.
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A congenitally acquired Toxoplasma gondii infection is gen­
erally treated with the combination of pyrimethamine and sul­
fadiazine (37). Both components are inhibitors of folate me­
tabolism, acting synergistically to suppress the proliferation of 
the parasite by indirect impairment of DNA synthesis (16, 48).
Several studies in mice revealed that the combination of
pyrimethamine and sulfadiazine reduces the parasitic load and 
prolongs the survival of mice after infection with a lethal dose 
of T. gondii (14, 31, 32). Studies on the effectiveness of py­
rimethamine and sulfadiazine for the treatment of congenital 
T. gondii infections in humans, however, have been scarce. 
Those studies that have been reported in the literature are 
from France (10, 11, 20). Those 
tiveness of treatment with pyrimethamine and sulfadiazine af­
ter fetal infection had been proven. The studies revealed that 
in utero treatment significantly reduced the number of infected 
offspring with severe toxoplasmosis. In addition, a relative de­
crease in benign to subclinical forms of infection was found. 
However, several of the offspring were still found to have 
intracranial calcifications or retinal scars which developed into 
chorioretinitis (10, 11, 20). It is not known whether these find­
ings were due to the fact that the onset of treatment was
concentra-
(I-,*  -T* . *• > • I»”  **-• , ,  • I J ,  I h j
iitvj* Corresponding author. Mailing address: University Hospital 
Radboud” Nijmegen, Department of Medical Microbiology, P.O. Box 
9101, 6500 MB Nijmegen, The Netherlands. Phone: 31 80 614356. Fax: 
31 80 540216.
amine and ; in s were toopyr
low to be effective.
On the other hand, the effects described by
(10, 11, 20) cannot solely be attributed to py­
rimethamine and sulfadiazine, since all patients 
treated with spiramycin throughout pregnancy, from the mo­
ment that maternal infection was diagnosed or suspected. An 
effect of the antibiotic cannot be ignored. A former study in the 
rhesus monkey showed that spiramycin reduces the parasitic 
load to undetectable levels in congenitally infected fetuses 
(40). Therefore, some of the effects in the French studies may 
have
In
caused by spiramycin, 
present study, the efficacy of pyrimethamme-sulfadi
i n
started early after the onset of fetal infection.
of the pharmacokinetics of these drugs 
were performed in this animal species 
tion of the dosaae regimen. Although extensive studies have
armac
in a of animals, little is
known about 
keys. The disposition of sulfadiazine has
s mon
m
of 0.5 to 1.5 years of age (29, 
However, results obtained in immature monkeys may be of 
limited relevance to adult monkeys, as has been found in pigs
The kinetics of sulfadiazine in adult monkeys have not 
reported. The pharmacological studies of pyrimethamine 
in rhesus monkeys by Schmidt et al. (38) focused mainly on 
tissue localization,
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In the present study the kinetic parameters of py­
rimethamine and sulfadiazine were determined in adult mon­
keys receiving a drug regimen that is applied to humans for the 
treatment of congenital T. gondii infections. Following this, 
transplacental transfer and the distributions of the drugs in 
tissue were investigated in pregnant monkeys. The effects of 
the treatment are related to the concentrations of py­
rimethamine and sulfadiazine that are reached in the fetus.
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MATERIALS AND METHODS
Monkeys. All monkeys were derived from the Laboratory Animals Breeding 
Experimental Farm of Shunde Guangdong, Beijing, People’s Republic of China, 
Breeding of the monkeys and animal care have been described before (43).
The treatment group consisted of 10 female monkeys (monkeys D1 to DIO) 
that were seronegative for antibodies to 71 gondii before the experiments were 
started. A group of four untreated monkeys (monkeys A 6 to A9), in whose 
fetuses infection had been proven, served as controls. This control group has 
been described in detail before (41). The purpose of the former study was to 
investigate whether the rhesus monkey was a suitable animal for use in the study 
of congenital 7! gondii infections (41). In addition, we meant to use this group of 
monkeys as untreated controls. The outcome of fetal infection in the control 
group is summarized in this report. The fetuses and babies of the monkeys are 
indicated by D fl to D fl() for the treatment group and A (6 to Af9 for the control 
group.
The pharmacokinetics of pyrimethamine and sulfadiazine were studied in two 
nonpregnant monkeys (monkeys E and F) after oral administration of a single 
dose of 1 mg of pyrimethamine per kg of body weight in combination with 50 mg 
of sulfadiazine per kg of body weight.
Pharmacokinetic studies with two nonpregnant monkeys. Tablets of py­
rimethamine (Daraprim) were obtained from Wellcome Pharmaceuticals, 
Utrecht, The Netherlands, and capsules containing sulfadiazine were provided by 
the Department of Clinical Pharmacy of the University Hospital Nijmegen. 
Sulfadiazine was obtained from the Onderlinge Pharmaceutische Groothandel 
(Utrecht, The Netherlands).
The pharmacokinetics of pyrimethamine and sulfadiazine were studied in 
nonpregnant monkeys E and F after oral administration of 1 mg of py- 
rimethamine per kg in combination with 50 mg of sulfadiazine per kg. These 
dosages were chosen because they are normally used to treat congenital 71 gondii 
infections in humans (27, 34, 37).
Pulverized pyrimethamine and sulfadiazine were hidden in a small hole within 
a LIGA biscuit (General Biscuits Nederland BV, Rozendaal, The Netherlands) 
covered with marmeladc or in a small piece of banana, and the monkeys were 
given the food.
Blood samples of 5 ml were collected from the vena mediana just before and 
at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, and 96 h after drug administration, The 
blood samples were centrifuged at 800 X g for 10 min. The sera were collected 
and stored at — 20°C until analysis.
Experimental design and collection of clinical samples. A time schedule of 
sample collection is shown in Fig. 1A. A 71 gondii infection was induced in the 
monkeys at day 90 of pregnancy. The time point of infection is comparable to the 
second trimester of organogenetie development in humans, The infection was 
induced by intravenous inoculation of 5 X 10h tachyzoites of 71 gondii (RH 
strain). Maternal parasitemia was tested for 8 days after inoculation of the 
monkeys, at amniotic punctures, and at the time of delivery by cesarean section 
as described before. In brief, all clinical samples (blood, amniotic fluid, placenta, 
and fetal tissues) were tested for the presence of 71 gondii by inoculation of mice 
(44) and by nested PCR (39, 41),
Fetal infection in the control group was tested 10 days after inoculation of the 
mother by examination of fetal blood and amniotic fluid. The transmission of 
infection was examined again at birth by testing the amniotic fluid and the blood 
and tissues of the neonates (Fig. IB) (41).
To monitor the effect of treatment during pregnancy, two additional samples 
obtained by amniotic puncture were included in the protocol for the treatment 
group. Amniotic fluid samples were thus obtained at 10, 25, and 40 days after 
inoculation of the mother (Fig, 1C). A cesarean section was performed at day 160 
of pregnancy, which was about 10 days before the expected date of delivery. 
Amniotic fluid, placental tissue, and neonatal blood from the umbilical cord were 
collected and tested for the presence of 71 gondii. The mothers and neonates 
were sacrificed, and autopsies were performed. The heart, brain, spleen, liver, 
and lungs were examined for the presence of 71 gondii
Processing of clinical samples. The protocols for the processing of the clinical 
samples have been described in detail previously (40, 41, 44). In brief, 6 ml of 
amniotic fluid was collected at each amniotic puncture. Two mice were each 
inoculated intraperitoneally with 1 ml of amniotic fluid to test for the presence 
of 71 gondii The remaining 4 ml was divided into portions of 1 ml each, and each 
portion was centrifuged at 800 x g for 10 min. The sediments of each portion 
were resuspended in 100 |Jil of physiological salt solution. DNA was isolated from 
two portions with guanidinium thiocyanate and silica particles exactly as de­
scribed by Boom et al. (6). The remaining two portions were stored at -80°C.
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FIG. 1. (A) Time schedule of sample collection during pregnancy. I, infec­
tion, 90 days after conception; C, collection of maternal blood for control of 
parasitemia; AP, amniotic puncture; FBS, fetal blood sampling; CS, delivery by 
cesarean section. During fetal blood sampling both amniotic fluid and fetal blood 
were collected. During delivery by cesarean section amniotic fluid, neonatal 
blood, and the placenta were collected. Delivery by cesarean section was fol­
lowed by autopsy of the neonate, and the heart, spleen, brain, and liver were 
obtained. All samples were tested for the presence of 71 gondii. (B) Results for 
the four monkeys in the control group that received no treatment. The detection 
of 71 gondii in the amniotic fluid and/or neonatal tissues is indicated with a plus 
sign, A premature birth is indicated by an arrow and the duration of pregnancy. 
+ *, fetal infection proven by the demonstration of antibodies in the neonate at 
serological follow-up. (C) Results for the six monkeys in the study group that 
were treated with pyrimethamine-sulfadiazine. The detection of 71 gondii in the 
amniotic fluid is indicated with a plus sign. The days at which treatment with 
pyrimethamine-sulfadiazine was started are marked with arrows.
The placenta and neonatal organs were homogenized in physiological salt 
solution as described before (40). Each sample was tested in duplicate for the 
presence of parasites by inoculation into mice. DNA was isolated from the tissues 
by incubation in 6% /^aminosalicylic acid-1  % NaCl-10 mM EDTA with 0.5 jig 
of proteinase K per ml at 37WC for 3 h. After phenol extraction, the DNA was 
precipitated overnight at -20°C. One microgram of the tissue DNA was tested 
for the presence of 71 gondii by a nested PCR on the ribosomal DNA gene as 
described before (39, 41).
Treatment with pyrimethamine and sulfadia2ine. Treatment with py­
rimethamine and sulfadiazine was started as soon as congenital infection was 
proven by detection of the parasite in the amniotic fluid and was continued until 
the mother gave birth. Transmission of infection occurred in 6 of the 10 monkeys 
of the treatment group (monkeys D2, D3, D 6, D7, D9, and DIO). The efficacy of 
pyrimethamine-sulfadiazine was studied in these six monkeys. The monkeys were 
treated orally with 1 mg of pyrimethamine per kg/day and 50 mg of sulfadiazine 
per kg/day. The drugs were administered as described above in the section on 
pharmacokinetic studies, In addition, folinic acid (3.5 mg) was administered 
orally once a week in order to counteract the bone marrow suppression caused 
by pyrimethamine (37). The cookies and bananas containing the drugs were 
always eaten eagerly, and the complete dose was consumed. Two monkeys, D3 
and D9, refused the dose once.
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1 oxic side c II cl  is ¡is a result oi the treatment were monitored by making serial 
blood counts of leukocytes and differentiation of lymphocytes.
Determination of drug concentrations. The concentrations of pyrimethamine 
iIIkI sulfadiazine were determined in the sera and tissues of the mothers and 
lotuses  ^ and in amniotic fluids by high-performance liquid chromatography 
(HPLC). Tissue samples were homogenized in physiological salt solution (4 ml/g 
[wet weight] of tissue) with an Ultraturax apparatus (Ystral GmbH, Dottingen, 
Germany). The crude homogenate was pelleted by centrifugation at 1,000 X g  for 
20 min. Hie supernatant was used for determination of drug concentrations by 
HPLC. For determination of the pyrimethamine concentration, 200 |i.l of the 
samples (serum, supernatant of the tissues, and amniotic fluid) was deprotein- 
ized with 200 jxl of acetonitrile. The samples were vortexed and centrifuged at
4,000 x g  for 10 min. Deproteinization of the samples (200 jxl) for determination 
of the sulfadiazine concentration was done with 300 |xl of 0.33 M perchloric acid. 
Aliquots of 50 |il of the prepared samples were injected onto the analytical
Determination of the pyrimethamine concentration was performed on a col­
umn packed with Spherisorb 5 ODS (particle size, 5 |xm; 4.6 by 250 mm [inner 
diameter|; Chrompack, Middelburg, The Netherlands). The mobile phase con­
sisted of 2 g ol 11.,PC)., (85%; wt/wt) and 0.6 g of telrarnethylammonkimehloride 
in 1 liter of water mixed with 1 liter of acetonitrile (vol/vol) and was run at a flow 
rate of 1.5 ml/min. UV detection was achieved at 220 nm. The quantitation limit 
of pyrimethamine was 0.05 p-g/ml at a signal-to-noi.se ratio of 3. The pure 
pyrimethamine that was used as a reference in HPLC was kindly provided by The 
Wellcome Foundation (Kent, England).
Sulfadiazine was measured by gradient HPLC analysis. The HPLC system 
consisted of a Dynamax 6.0-nm C8 column (particle size, 8 fxm; 4.6 by 250 mm 
[inner diameter); Raimn Instruments Co. Inc., Woburn, Mass.). At time zero, the 
eluent consisted of 10% acetonitrile and 90% of a Wo acetic acid solution in 
water. In 18 min the eluent changed linearly to 28% acetonitrile and 72% acetic 
acid (1%). The flow rate for the solvent was 1.5 ml/min, and detection was 
achieved at 272 nm. The detection limit of sulfadiazine was 0.2 ng/ml at a 
signal-to-noise ratio of 3.
The intraday and interday coefficients of variation were calculated for serum 
samples. The coefficients were found to be 6.4 and 7.7%, respectively, for py­
rimethamine and 3.2 and 1.9%, respectively, for sulfadiazine.
Curve fitting (r2 >  0.97) and estimation of pharmacokinetic parameters were 
done with the aid of the computer programm MW/PHARM (33).
Statistical evaluation. Fisher’s exact test for the comparison of proportions 
was used to compare the probabilities of infection in the treatment and control 
groups. Furthermore, 80 and 95% confidence intervals were calculated for an 
infection-free outcome of therapy. The confidence intervals were based on a 
binomial distribution (5).
RESULTS
Pharmacokinetic studies. The pharmacokinetics of py­
rimethamine and sulfadiazine were determined after oral ad-
conc pyr [ug/ml]
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time [hours]
FIG. 2. Concentrations of pyrimethamine (pyr) in the sera of monkeys E (*) 
and F (□) after oral administration of 1 mg/kg when given in combination with 
50 mg of sulfadiazine per kg.
lives were found to be 44.4 h for pyrimethamine and 5.2 h for 
sulfadiazine. A maximum concentration in serum, of 58.7 |xg of 
sulfadiazine per ml was reached at 3.7 h after administration. 
At 2.7 h after administration of 1 mg of pyrimethamine per kg 
a peak concentration of 0.22 (xg/ml in serum was found.
Treatment of congenital T. gondii infections. The 4 monkeys 
in the control group and the 10 monkeys in the treatment 
group all developed a parasitemia that lasted for about 10 days. 
Parasitemia was demonstrated by the isolation of parasites 
from maternal blood by both mouse inoculation and detection 
by PCR.
As described in detail in our previous report (41), T. gondii 
was detected in four of the nine fetuses of the control group 
(Af6 to Af9). The results are summarized in Figure IB.
Fetal infection in the treatment group was monitored pre- 
natally by sequential testing of amniotic fluid samples obtained 
by puncture at days 100,115, and 130 of pregnancy. Transmis-
ministration of 1 mg of pyrimethamine per kg with 50 mg of sion of infection was found in 6 of the 10 monkeys (Df2, Df3, 
sulfadiazine per kg to nonpregnant monkeys E and F. The Df6, Df7, Df9, and Df10). The parasite was detected by PCR in 
concentrations of pyrimethamine and sulfadiazine in serum are the amniotic fluid of all six monkeys, whereas mouse inocula-
presented in the Fig. 2 and 3, respectively. tion was positive only for monkeys Df2, Df9, and Df10. In four
T serum concentration-time curves of both pyrime- of six monkeys, the transmission of infection occurred within
thamine and sulfadiazine fit best to a one-compartment model 10 days after inoculation of the mother, in monkey D7 between
Flie pharmacokinetic parameters that were calculated from days 10 and 25, and in monkey D10 between days 25 and 40 
these data are shown in Table 1. The serum elimination half- (Fig. 1C).
Drug and monkey
F
Mean In ¿¿»A it 2 )
TABLE I. Pharmacokinetic parameters of pyrimethamine and sulfadiazine in rhesus monkeys"
« M l
7’m.w ( 1'  )
1.0
4.3
2.7
C mux
0.22
0.22
0.22
V (liters)
4.5
4.1
4.3
MRT (h)
87.0
42.7
64.9
AUC 
(h • (xg/ml)
19.3
8.2
14.6
AUC, tr 
(h • ]xg/ml)
8.2
8.0
8.1
h a  01)
60.2
28.6
44.4
CL
(liters/h)
0.05
0.10
0.08
adiazine
*
F
Mean (n 2)
4.3
3.0
3.7
53.2 
64.1 
58.7
0.54
0.54
0.54
10.3
8.9
9.6
711
676
694
680
675
678
5.3
5.0
5.2
0.07
0.07
0.07
" Tile values for the 
lime lo maximum concentration of 
residence time; AUC, area under 
clearance.
max*_.ic parameters were determined after oral administration of 1 mg of pyrimethamine per kg with 50 mg of sulfadiazine per kg. T, 
drug in serum; Cmnx, maximum concentration of drug in serum; V, volume of distribution of the central compartment; MRT, mean 
the concentration-time curve; AUC, tr, area under the concentration time curve, trapezoidal rule; l t/2, half-life; CL, total plasma
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FIG, 3. Concentrations of sulfadiazine (sulfa) in the sera of monkeys E (*) 
and F (□) after oral administration of 50 mg/kg when given in combination with 
1 mg of pyrimethamine per kg.
As shown in Fig. 1C, treatment was started in the six mon­
keys shortly after collection of the amniotic fluid samples and 
infection was proven. In four monkeys (monkeys D2, D3, D6, 
and D9) the time interval between collection of the amniotic than the concentrations in serum. Both pyrimethamine and
amniotic fluid sample from any monkey collected 10 to 13 days 
after the initiation of treatment (Figure 1C).
Postnatally, the parasite was not found in neonatal tissues or 
amniotic fluids. The placenta of monkey DIO, which received 
treatment for 25 days, was the only sample found to be positive 
at birth. The placenta was found to be positive by PCR but not 
by mouse inoculation. No hematological side effects from the 
administered drug regimen were found.
Statistical evaluation of these results revealed that the infec­
tion rate in the treatment group was similar to the rate in the 
control group (P = 0.66). Furthermore, the outcome of fetal 
infection after treatment was significantly different from the 
outcome in the control group (P = 0.033). The confidence 
intervals were calculated for this small number of animals; the 
80% confidence limits were 0 to 28%, whereas the 95% con­
fidence limits were 0 to 40%. The drug concentrations at which 
these effects occurred are given in Tables 2 and 3. The time 
interval between the last dose and the collection of samples 
was 4 h for monkeys D3 and D10 (peak levels) and about 26 h 
for monkeys D2, D6, D7, and D9 (trough levels). The concen­
trations in fetal serum varied from 0.05 to 0.14 |xg/ml for 
pyrimethamine and from 0.6 to 5.4 (ig/ml for sulfadiazine. 
Pyrimethamine was found to accumulate in the soft tissues, 
especially in the spleen and the lungs. Sulfadiazine was also 
found in the tissues, but the concentrations were always less
fluid sample and the initiation of treatment was only 2 days. 
The parasite was no longer detectable in the next consecutive
sulfadiazine crossed the placenta of the rhesus monkey very 
well, as shown in Table 4. Pyrimethamine penetrated into brain
TABLE 2. Concentration of pyrimethamine
Sample (day of collection)*1
Pyrimethamine concn (|xg/ml or |xg/g)
Monkey D2 Monkey D6 Monkey D9 Monkey D7 Monkey D3,! Monkey D10'1
Maternal blood (115) <0.05 <0.05 <0.05 NT' <0.05 NT
Maternal blood (130) <0.05 0.09 <0.05 0.09 <0.05 NT
Maternal blood (160) <0.05 0.11 <0.05 0.11 0.21 0.30
Maternal brain*7 0.30 <0.05 0.25 0.30 <0.05 0.85
Maternal heart'7 <0.05 1.3 0.35 <0.05 <0.05 0.30
Maternal spleen'7 0.95 0.8 0.50 1.40 <0.05 2.40
Maternal liver'' 0.70 1.0 0.90 1.60 2.0 2.50
Amniotic fluid (115) <0.05 <0.05 <0.05 NT <0.05 NT
Amniotic fluid (130) <0.05 <0.05 <0.05 <0.05 <0.05 NT
Amniotic fluid (160) <0.05 0.06 <0.05 0.07 <0.05 0.13
Fetal blood (130) <0.05 <0.05 <0.05 <0.05 <0.05 NA‘‘
Fetal blood (160) <0.05 <0.05 <0.05 0.09 0.08 0.14
Placenta (I60)'y <0.05 <0.05 <0.05 0.60 0.40 2.50
Fetal brain'* 0.30 <0.0 5 <0.05 <0.05 0.30 0.65
Fetal heart'7 <0.05 <0.05 <0.05 0.35 <0.05 0.95
Fetal spleen 1.10 0.50 0.50 1.0 1.05 ND''
Fetal liver*7 <0.05 <0.05 <0.05 <0.05 <0.05 0.50
Fetal lung'7 1.15 1.05 1.6 1.95 0.45 6.0
Duration of treatment (days) 58 58 58 40 58 25
" The day of sample collection corresponds to pregnancy duration.
h The average time interval between the last dosing and sample collection was 26 h. Thus, the concentrations in serum presented here are mainly trough levels. For 
monkeys D3 and DIO at day 160 of pregnancy, the time interval was 4 h.
' NT, no treatment at that moment.
d The concentrations in tissue were determined by using tissue extracts which were diluted five times in physiological salt solution. If a concentration in tissue was 
found to be <0.05 |xg/ml, this means that this was the concentration in the diluted sample.
NA, sample not available.
1 ND, not done.
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» Y 1
5 LE 3. Concentration o f sulfadiazine
Sample (day of collection)“
Monkey D6
Sulfadiazine concn (fxg/ml or (J-g/g)
M onkey D 2 Monkey D9 Monkey D7 Monkey D3h Monkey D10h
Maternal blood (115) 4.1 7.4 17.6 N T 3.9 NT
Maternal blood (130) 5.3 2.3 2.2 1.0 2.5 NT
Maternal blood (160) 4.6 1.9 3.3 3.4 5.7 6.0
Maternal brain** 1.75 <0.2 1.6 1.2 2.3 1.95
Maternal heart'* 2.35 <0.2 1.2 1.4 2.1 1.25
Maternal spleen'* 3.45 <0.2 2.0 2.3 4.55 3.2
Maternal liver'* 2.85 <0.2 2.25 <0.2 2.15 3.6
Amniotic fluid (115) 7.5 4.0 0.75 NT 3.9 NT
Amniotic fluid (130) 5.3 2.6 1.7 1.2 2.9 NT
Amniotic fluid (160) 4.0 2.7 2.0 5.4 4.2 4.4
Fetal blood (130) 4.8 2.0 1.7 0.6 1.0 NA*
Fetal blood (160) 4.0 1.9 3.2 3.7 5.1 5.4
Placenta** 3.1 <0.2 1.55 2.4 2.45 2.4
Fetal brain'* 1.3 0.55 1.0 1.45 1.2 2.35
Fetal heart'* 2.7 <0.2 1.4 2.0 1.9 1.95
Fetal spleen'* 3 954 <*w  m - r <.0.2 2.15 2.3 2.65 3.5
Fetal liver** 2.75 <0.2 2.0 2.0 2.85 3.75
Fetal lung** 3.0 1.0 1.95 2.2 2.25 2.75
Duration of treatment (days) 58 58 58 40 58 25
a The day of sample collection corresponds to pregnancy duration,
h The average time interval between the last dosing and sample collection was 26 h. Thus, the concentrations in serum presented here are mainly trough levels. For 
monkeys D3 and DIO at day 160 of pregnancy, the  time interval was 4 h, 
c NT, no treatment at that moment.
c/ The concentrations in tissue were determined by using tissue extracts which were diluted five times in physiological salt solution. If a concentration in tissue was 
found to be < 0.2 fxg/rnl, this means that this was the concentration in the diluted sample. 
c? NA, sample not available.
.55* than the
rimethamine in the brain were about 
greater than the corres
aliens py- the growth of the parasite in vitro (12, 24, 42). The inhibition 
of growth was associated with a reduction in the number of
s in s
whereas the concentrations of sulfadiazine were to
and the number of intracellular parasites (12,
24). Pyrimethamine and sulfadiazine also cause morphological 
about 30% of the corresponding concentrations in serum (Ta- changes in the parasite, as demonstrated by electron micros-
ble 4). copy (42).
DISCUSSION
in mice have shown that treatment with py­
rimethamine and sulfadiazine prolongs survival after infection 
with a lethal dose of T. gondii by reducing the parasite load (14,
and Stadtsbaeder (31) found that mice treated
The antitoxoplasma activities of pyrimethamine and sulfadi­
azine have been demonstrated both in vitro and in vivo. Py­
rimethamine and sulfadiazine act synergistically on T. gondii, with pyrimethamine and sulfadiazine acquired no resistence to 
and it appeared that the combination o f  these drugs inhibits a lethal challenge with T. gondii. Treatment with pyrimethamine
TABLE 4. Transplacental passage and penetration into the brain of pyrimethamine and sulfadiazine
M P, pyrimethamine; S, sulfadiazine.
Drug" Drug ratio between the samples'1
ÉWW. ¿ a ( r e a»« t f t l l l lM tw /
Day of 
collection*' Monkey D2
Monkey Dù Monkey D9 Monkey D7 Monkey D3 Monkey DIO
P Fetal blood/maternal blood
■ w i m i i i i  mu ....................... . il n n iii'iim ,'...... ..
160 ND‘* ND ND 0.81 0.38 0.46
P Fetal brain/fetal blood 160 ND ND ND ND 3.75 4.6
P Maternal brain/maternal blood 160 ND ND ND 2.7 ND 2.8
S Fetal blood/maternal blood 130 0.90 0.87 0.77 0.60 0.40 NDs Fetal blood/maternal blood 160 0.87 1.0 0.97 1.0 0.89 0.90
s Fetal brain/fetal blood 16(1 0.33 0.29 0.31 0.39 0.24 0.44
s Maternal brain/maternal blood 160 0.38 ND 0.48 0.35 0.40 0.32
h Transplacental passage is expressed as the ra tio  between the concentration of the drug in fetal serum and the corresponding concentration in maternal serum. The 
ratio between the concentration in the brain and the corresponding concentration in serum gives an impression of the level of penetration of the drug into the brain.
** The day of sample collection corresponds to pregnancy duration. 
d ND, not determined because the drug concentration was below the detection level or because there was no treatment given at that moment.
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and sulfadiazine also prevented squirrel monkeys from dying of keys (29, 30). A similar finding was reported by Friis et al. (15)
an acute toxoplasmosis (17). in pigs, who found that the half-life of sulfadiazine decreased
Studies in humans revealed that treatment with py- with an increase in the ages of the pigs.
rimethamine and sulfadiazine significantly reduced the number The pyrimethamine half-life of 44.4 h found in rhesus mon-
of offspring with severe congenital toxoplasmosis (9-11, 20). keys is shorter than the 85 to 114 h reported in humans (8, 26).
Several children, however, were born suffering from subclinical When compared with those in babies, however, the half-life in
or even symptomatic toxoplasmosis, despite treatment with serum was only slightly shorter than the reported 64 ± 12 h
pyrimethamine and sulfadiazine (7, 10, 11, 20). The treatment (28). On the basis of the serum half-life of pyrimethamine
of these children was started after fetal infection had been observed in the rhesus monkey, a frequency of one dose every
proven. The prenatal diagnosis of infection was time-consum- '1 or 2 days would be appropriate. Because the half-life of
ing most of the time, and the studies contained no information sulfadiazine is 5.2 h, however, a more frequent dosing would be
about the duration of infection at the moment that therapy was required.
started. The time interval between the onset of fetal infection The pharmacokinetic studies were performed with nonpreg-
and the initiation of therapy was therefore possibly too long. In nant monkeys. Given the effects of pregnancy on the volume of
the present study the moment of infection was adequately distribution and renal blood flow, drug clearance could be
known. Because antenatal detection of T. gondii was per- different. Further investigation of these parameters needs to be 
formed by PCR, a result can be obtained within 2 days of performed to establish the dosages of the drugs in the treat-
receiving the sample, and treatment could be started early 
after the onset of fetal infection in our experimental setup. By 
PCR, transmission of infection was detected antenatally in six 
monkeys, whereas mouse inoculation was positive for only 
three monkeys. The high degrees of sensitivity and reproduc­
ibility of the PCR were also found in our former study (40). It 
has been stated before that PCR cannot discriminate between 
viable and dead parasites. However, since transmission of dead
ment of humans.
Weiss et al. (47) demonstrated that the concentration of 
pyrimethamine in the sera of mice should be at least 0.5 |xg/ml 
to be effective in inhibiting Toxoplasma growth. When py­
rimethamine was used in combination with sulfadiazine, the
|xg/ml
(jug/ml
tions that were found to be effective in vivo were in close
parasites is unlikely, the detection of T. gondii in amniotic fluid agreement with those that were found to be effective in vitro
by PCR is considered to be of clinical importance. (24, 42). Lower concentrations of 0.02 |xg of pyrimethamine
Statistical analysis of the results revealed that the rate of per ml in combination with 0.1 |xg of sulfadiazine per ml,
transmission of infection to the fetuses in the control group however, also had an inhibitory effect (12). Such concentra-
was similar to the rate in the treatment group. In addition, tions were easily reached in the rhesus monkeys by the inves-
treatment with pyrimethamine and sulfadiazine significantly tigated dose regimen. Concentrations of 5:25 |xg of sulfadia-
reduced the number of infected offspring compared with the zine per ml were present in the sera of adult monkeys for about
number of infected untreated controls. 10 h, and concentrations of ^0.1 |xg of pyrimethamine per ml
The efficacy of treatment was related to the concentrations were present in sera for more than 24 h after single oral dosing,
of the drugs that were reached in the fetus. Both py- Given the high rate of transplacental passage of both drugs, it
rimethamine and sulfadiazine can cross the placenta freely and is assumed that such effective concentrations in serum are also
are therefore thought to be appropriate drugs for use in the present in the fetus. On the basis of these findings a single dose
treatment of congenital T. gondii infection (13). The concen- pyrimethamine given every day would be appropriate. The
trations of pyrimethamine in the sera of neonates varied from half-life of sulfadiazine of 5.2 h and the time during which
38 to 81% of the corresponding concentrations in the sera of effective concentrations are present in serum, however, would
the mothers. The concentrations of sulfadiazine in the sera of 
the fetuses were similar to those in the sera of the mothers. 
The same results have also been found for transplacental pas­
sage of pyrimethamine and sulfadoxine in humans (13). This
require two doses per day. For practical reasons py­
rimethamine and sulfadiazine were administered together in a 
single dose.
Concentrations of 0.1 to 0.5 |xg of pyrimethamine per g were
was expected because rhesus monkeys and humans both pos- also reached in the tissues of the rhesus monkey. Because in 
sess a placenta of the hemochorial type (35). Since brain dam- most cases trough levels were measured, concentrations in
age is the most severe consequence of congenital toxoplasmo- H-g/ml
sis, the concentrations in the brain are of special interest. It was two monkeys (monkeys D3 and DIO), the levels in serum were 
found that pyrimethamine and sulfadiazine both can cross the measured approximately 4 h after administration of the last 
blood-brain barrier in the rhesus monkey. The concentrations dose. In these cases concentrations in serum greater than 0.1
of sulfadiazine in the brain were found to be about 35% of the |xg/ml
concomitant concentrations in serum for both the fetus and the tered drug regimen were found in the rhesus monkeys. Py- 
mother. These percentages are in close agreement with the rimethamine, however, should not be given in excess of dos-
levels of sulfadiazine that have been found in the cerebrospinal of 1.25 mg/kg/day since higher cannot be
fluid of dogs (45) and humans (46). Pyrimethamine was found tolerated by rhesus monkeys when they are administered re-
to penetrate and accumulate in monkey brain tissue, and con- peatedly (38). It should be mentioned, however, that in the
centrations up to 4.5 times the concomitant levels in serum study of Schmidt et al. (38) the treatment was not supple-
were found. This was already expected from experiments in mented with folinic acid, as was the case in the present study.
_A  m __ . .  . M  M . .  a- k - •  — -  _
humans (23), rhesus monkeys (38), and rats (8), in which sim­
ilar ratios of levels in brain to levels in serum were found.
At high doses pyrimethamine has been found to have terat­
ogenic effects in rats (19, 21, 43) and miniature pigs (18).
Pharmacokinetic studies revealed that pyrimethamine and Besides this, sulfadiazine should not be administered during 
sulfadiazine have serum half-lives of 44.4 and 5.2 h, respec- the last month of pregnancy because it increases the risk of 
lively, in the rhesus monkey. Sulfadiazine has a shorter elimi- kernicterus (48). Kernicterus was not investigated in the mon-
nation half-life in rhesus monkeys than in humans (1, 25, 36). 
In addition, the elimination half-life found in adult monkeys in 
the present study is shorter than that reported for young mon­
keys used in the present study, which were killed immediately
after birth.
The risk of teratogenic effects caused by pyrimethamine and
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the risk of kernicterus caused by sulfadiazine create a reluc- 
tance to use this drug cornbination for the prevention of trans­
mission of infection. Therefore, the safer antibiotic spiramycin 
is given as long as fetal infection has not been proven. A 
former study in rhesus monkeys showed that spiramycin is able 
to reduce the number of parasites in amniotic fluid to unde­
tectable levels (40). However, spiramycin had to be adminis- 
iired for at least 3 weeks to be effective (40). Treatment with
..... , • mc| suifac]iazjn0i on otiier hand, showed 
same effect within 10 to 13 days.
of malformations, the use of py­
rimethamine and sulfadiazine during pregnancy has been dis-
shed work, however, revealed no grounds for 
contraindication during pregnancy (2). On the basis of these 
findings, the drug combination instead of spiramycin should be 
used to prevent the transmission of infection because of the 
potent activity of the combination against T. gondii parasites.
last month of pregnancy (i.e., after 36 weeks or 
arlier if an anamnesis exists for premature birth) sulfadiazine
out because of the risk of kernicterus.
It appears from the results of the present study that the 
combination of pyrimethamine and sulfadiazine is an effective 
drug regimen for the treatment of congenital T. gondii infec­
tion. Pyrimethamine and sulfadiazine act on the proliferative 
stage of the parasite but not on cysts in tissues. The eradication 
of cysts is very important because of the risk of developing 
chorioretinitis later in life (22). Studies should focus on new 
drugs that cross the blood-brain barrier and that act on the 
cysts as well. Initial studies with atovaquone showed promising
4). On long-term probation, however, atovaquone 
was not able to eradicate the cysts from infected mouse brains
In conclusion, when administered early after the onset of 
fetal infection the combination of pyrimethamine and sulfadi­
azine is an effective drug regimen for the treatment of congen­
ital T. gondii infections.
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